The identification of a novel splicing mutation in  in a Japanese family with C1q deficiency: a case report by unknown
Higuchi et al. Pediatric Rheumatology 2013, 11:41
http://www.ped-rheum.com/content/11/1/41CASE REPORT Open AccessThe identification of a novel splicing mutation
in C1qB in a Japanese family with C1q deficiency:
a case report
Yousuke Higuchi1, Junya Shimizu1*, Michiyo Hatanaka2, Etsuko Kitano2, Hajime Kitamura2, Hidetoshi Takada3,
Masataka Ishimura3, Toshiro Hara3, Osamu Ohara4, Kenji Asagoe5 and Toshihide Kubo1Abstract
C1q deficiency is a rare disease that is associated with a high probability of developing systemic lupus
erythematosus. We report a 4-year-old Japanese girl who presented with fever, facial erythema, joint pain, and oral
ulceration. Complement deficiencies were suspected because of her persistent hypocomplementemia and normal
levels of the complement proteins C3 and C4. We identified a novel homozygous splicing mutation in the C1qB
gene, c.187 + 1G > T, which is the first mutation to be confirmed in a Japanese individual. Because treatment with
steroids and immunosuppressive drugs was not effective, we commenced use of fresh frozen plasma to provide
C1q supplements. Currently, the patient remains almost asymptomatic, and we are attempting to control the drug
dosage and administration intervals of fresh frozen plasma.
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The complement system involves a group of proteins
that function as part of the immune system. Three com-
plement pathways make up the complement system, the
classical, alternative, and lectin pathways. The C1q pro-
tein is the first component of the classical pathway and
is composed of the C1qA chain, C1qB chain, and C1qC
chain, which are encoded by C1qA, C1qB, and C1qC
genes, respectively [1].
C1q deficiency is a rare disease that is associated
with a high probability of developing systemic lupus
erythematosus (SLE) [2,3]. It is also complicated by
cutaneous disease, glomerulonephritis, central nerve
system lupus, and recurrent bacterial infection at an
early age [2,4]. A deficiency of other complement com-
ponents such as C1r, C1s, C2, and C4 is also involved
in SLE, with C1q deficiency being the strongest single
risk factor for SLE development [5]. The first C1q
deficiency-causing mutation was reported by McAdam* Correspondence: junshimi@okayama3.hosp.go.jp
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reproduction in any medium, provided the oret al. in 1988 [6]. Today, 14 mutations have been iden-
tified, all of which are nonsense or missense mutations
[7-9]. Although immunosuppressive therapy is admin-
istered to C1q deficiency patients, there is currently no
curative therapy.
We report herein a girl with C1q deficiency, and the
identification of a novel splice site mutation in the C1qB
gene, which is the first confirmed genetic mutation in a
Japanese individual with C1q deficiency.Case presentation
A 4-year-old Japanese girl was referred to our hospital
with a three month history of fever, facial erythema,
joint pain, and oral ulceration. She had been diagnosed
with discoid lupus erythematosus following a skin bi-
opsy at another hospital. Her symptoms were alleviated
transiently after the oral administration of prednisolone;
however, they relapsed after cessation of treatment. She
had no past history of recurrent infections or fevers of
unknown origin. Her parents are not consanguineous,l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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two brothers, were healthy and had not complained of
SLE-like symptoms at that time.
At the first visit to our department, physical examina-
tions revealed low grade fever, scarring facial erythema,
oral ulceration, and a chilblain-like rash on the extrem-
ities of her limbs (Figure 1). Breath sounds were clear
and unlabored. Cardiac examination revealed no mur-
murs, rubs, or gallops. The abdomen was soft, nonten-
der, and nondistended. Neurological examinations of
the cranial nerve, motor strength and coordination,
reflexes, gait and sensation were normal. Blood and
urine tests for rheumatic fever and other febrile illness
revealed elevated inflammatory markers (erythrocyte
sedimentation rate (ESR) 65 mm/60 min, C-reactive
protein (CRP) 1.32 mg/dl), although blood cell count,Figure 1 Lupus erythematosus malar skin rash and rash on the
hand and foot of our patient.electrolytes, blood urea nitrogen, creatinine, liver func-
tion, and urinary tests were all normal (Table 1). Total
complement activity (CH50) was not detectable but an
immunoturbidimetric assay revealed that C3 and C4
levels were within the normal range. Speckled antinu-
clear antibody and rheumatoid factor were positive, and
anti-double stranded DNA IgG antibody levels were
negative. A chest computed tomography (CT), echocar-
diography, magnetic resonance imaging of the brain,
and renal biopsy specimen were normal.
Initially, the patient had been diagnosed with SLE and
had received prednisolone and mizoribine treatment.
Although symptoms ameliorated immediately, CH50
remained consistently negative during a period of six
months, whereas C3 and C4 were within the normal
range. Antinuclear antibody and rheumatoid factor
levels gradually elevated, but anti-double stranded DNA
IgG antibody levels were still negative. From the above
discrepancy between symptoms and laboratory data
changes, we suspected complement deficiency so inves-
tigated her complement system in detail. Serum C1q
levels measured at SRL Inc. (Tokyo, Japan) by nephe-
lometry were 2.8 mg/dl (normal range: 8.8–15.3 mg/dl).
Further analysis of the complement systems revealed
that whole alternative complement pathway activity
(ACH50) and C4 and C2 activities were within the nor-
mal range, whereas C1 activity was very low (Table 2)
[10-13]. The addition of purified human C1 subcompo-
nent enabled CH50 to be restored to a normal range
only when C1q was added, but neither C1r nor C1s was
effective (Table 3). For this reason, we strongly suspected
a C1q deficiency.
Genomic DNA was extracted from EDTA-blood cells
using standard procedures. PCR primers were designed
to amplify all exons and exon-intron boundaries of
C1qA, C1qB and C1qC genes. Table 4 shows the primer
sets and sequencing performed with the BigDye ter-
minator v3.1 Cycle Sequencing Kit. Sequence analysis
revealed a novel homozygous splice site mutation in
C1qB, c.187 + 1G > T (Figure 2), but no other muta-
tions. Reverse transcriptase-polymerase chain reaction
amplification of C1qB demonstrated the presence of an
abnormal single band on gel electrophoresis caused by
a splicing error of intron 2/intron 3 (Figure 3). Combined
with the complement assay, this DNA sequencing result
enabled the molecular diagnosis of C1q deficiency to be
confirmed. Mutation analysis and CH50 measurements of
family members demonstrated that the patient’s parents
and one sibling were heterozygous for c.187 + 1G > T with
normal CH50 levels. The second sibling (0 years old) with
undetectable CH50 levels was also homozygous for the
mutation (Figure 4).
After about one year from the first visit, the patient
experienced a recurrent fever every few days with no
Table 1 Laboratory findings on first visit of patient
Blood test Result Normal range Blood test Result Normal range
WBC 6600/μl 4500–15500 CRP 1.32 mg/dl <0.1
Seg 5600/μl 1500–8500 ESR 60 min 65 mm/60 min 0–15
Ly 660/μl 1200–8000
RBC 379 × 104/μl 390–490 CH50 <12.0 CH50/ml 22–40
Hb 10.7 g/dl 11.4–14.2 C3 122 mg/dl 71–159
Ht 30.5% 34–40 C4 45 mg/dl 13–30
Plt 15.2 × 104/μl 14.0–45.0 RF 31 IU/ml <40
AST 31 IU/l 18–63 ANA(speckled) 1:320 <1:40
ALT 21 IU/l 20–50 Anti-dsDNA IGG <10 IU/ml <10
LDH 297 IU/l 142–297 Anti-Sm 1:2 <1:2
Na 141 mEq/l 134–143 Anti-RNP 1:16 <1:2
K 3.3 mEq/l 3.4–4.9 Anti-Ro (−) (−)
Cl 104 mEq/l 98–107 Anti-La (−) (−)
Ca 9.0 mg/dl 8.8–10.3
TP 6.3 g/dl 5.6–7.7 Urinalysis
Alb 3.8 g/dl 3.1–4.8 U-protein (−) (−)
BUN 6 mg/dl 5–27 U-glucose (−) (−)
Cre 0.40 mg/dl 0.30–0.90 U-occult blood (−) (−)
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nisolone (15 mg/day) and mizoribine (300 mg/every
other day), fever and erythematosus rash were aggra-
vated and the ESR elevated to 68 mm/60 min, which is
the index that most reflects her condition. We carried
out intravenous methylprednisolone pulse therapy, but
the effect was only temporary. Accordingly, we initi-
ated fresh frozen plasma (FFP) transfusion for supple-
mentation of C1q. Immediately after transfusion of
FFP (10 ml/kg), her CH50 levels recovered to within
the normal range but became undetectable 24 h later
(Table 5). Nevertheless, she remained afebrile and her
rash improved slowly, while ESR declined to 37 mm/
60 min following once weekly administration of FFPTable 2 Analysis of complement system activity
Hemolytic activity NHS Patient serum Reference value
CH50 (U/ml) 125 0 90–160
(NHS %) 100% 0%
ACH50 (U/ml) 18.5 18.9
(NHS %) 100% 102% 70–130%
C1 activity (U/ml) 1450 100
(NHS %) 100% 7% 70–130%
C2 activity (U/ml) 400 360
(NHS %) 100% 90% 70–130%
C4 activity (U/ml) 2000 1600
(NHS %) 100% 80% 70–130%
NHS normal human serum, ACH50 alternative complement pathway activity.(10 ml/kg). We are currently attempting to slowly
reduce the prednisolone dosage and the frequency of
FFP.Conclusions
We report a girl diagnosed with SLE because of C1q
deficiency caused by a novel homozygous splice site
mutation in C1qB. C1q deficiency is a rare autosomal
recessively inherited disease, with only 41 patients
from 23 families reported in 1998 [2]. More recently,
C1q deficiency has been confirmed in 64 cases within
38 families, 88% of which present with SLE or SLE-




Patient serum + C1q (U/ml) 140
(NHS %) 112%
Patient serum + C1r (U/ml) 0
(NHS %) 0%
Patient serum + C1s (U/ml) 0
(NHS %) 0%
Patient serum + activated C1s (U/ml) 0
(NHS %) 0%
NHS normal human serum.
Table 4 List of primers used in this work
Primer name Gene Exon F/R Primer sequence (5’-3’) Tm (°C) Annealing Tm (°C)
C1QA-02-F C1qA 02 F TTGTGTGCATGGGACTCAAG 56 60
C1QA-02-R C1qA 02 R GGCCAAGTCAGGCCAAG 58
C1QA-03a-F C1qA 03a F TCCCTGAGGACCAGTAGGC 60 60
C1QA-03a-R C1qA 03a R GGACAGGCAGATTTCCCAC 58
C1QA-03b-F C1qA 03b F TCATCTTCGACACGGTCATC 56 60
C1QA-03b-R C1qA 03b R ATTTTACAGGCGGAGCATGG 56
C1QB-02-F C1qB 02 F GGATGCAGATGGAGGGATAG 58 60
C1QB-02-R C1qB 02 R AGGCAACTGTGACTTGGGAG 58
C1QB-03a-F C1qB 03a F GCAGGCCTCCTTCTTTTGG 58 60
C1QB-03a-R C1qB 03a R TCACGCACAGGTTCCCTC 58
C1QB-03b-F C1qB 03b F CAGACCATCCGCTTCGAC 58 60
C1QB-03b-R C1qB 03b R GGGGTAGAGTGAGCGTTGC 60
C1QC-02-F C1qC 02 F ATCCATGGTGAGGCTCCTG 58 60
C1QC-02-R C1qC 02 R CCCAGACAGACACTCTGATCC 60
C1QC-03a-F C1qC 03a F GTTCCCTGGAAGACACCCTC 60 60
C1QC-03a-R C1qC 03a R TATGCGACGCGTGGTAGAC 58
C1QC-03b-F C1qC 03b F AGCCTGATCAGATTCAACGC 56 60
C1QC-03b-R C1qC 03b R TGGCCAGTAAGGTGGGTCC 60
F forward, R reverse, Tm temperature.
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ship between C1q deficiency and SLE or SLE-like
disease. The first is that C1q deficiency causes auto-
immunity by impairing the clearance of apoptotic
cells [2], while in the second the absence of C1q
affects the negative selection of autoreactive B cells
[14]. The third is that the lack of C1q leads to
increased interferon-α production and the defectiveFigure 2 Sequence analysis of the C1qB gene. A homozygous mutation
caused by a G-to-T transversion (c.187 + 1G > T).regulation of dendritic cells [15]. It has also been
reported that C1q activates canonical Wnt signaling,
which regulates T cell development and dendritic cell
maturation [16-18]. The suppression of Wnt signal-
ing in association with C1q deficiency may result in
the inadequate activation of lymphocytes.
The majority of C1q deficiency patients are European
or Middle Eastern, with only four cases reported towas identified at the consensus splicing donor site in intron 2–3
Figure 3 Reverse transcriptase-polymerase chain reaction analysis of C1qB mRNA. A single band observed at 1458 bp was caused by a
splicing error of intron 2–3. 1 kb+, 1,000 bp DNA-ladder marker; Pt., patient; C., normal control; NTC, no template control.
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analysis [7,19-22]. Al-Mayouf et al. reported that C1q
deficiency patients tend to develop SLE in less than
five years [4]. Our patient also developed SLE at the
age of four, with persistent hypocomplementemia and
normal C3 and C4 levels. We believe that the possibil-
ity of C1q deficiency should therefore always be con-
sidered in such cases. To our knowledge, 14 different
C1q deficiency-causing mutations have been identified
to date, most in European and Middle Eastern patients,
with one in an African-American ancestry [7-9]. All
are missense or nonsense mutations, so the present
mutation is the first report of a splicing error associ-
ated with the disorder.
Previously reported complications of C1q deficiency
include glomerulonephritis in 30%, central nervous
system involvement in 19%, and bacterial infections in
41% of patients [7]. Moreover, symptoms present withFigure 4 Pedigree showing the heterozygosity of the patient’s
parents and older brother, and the homozygosity of her
younger brother, for c.187 + 1G > T.varying degrees of severity, even in the same family
[23]. It is possible that environmental factors such as
exposure to ultraviolet radiation or a history of infec-
tion may affect the epigenetic regulation of developing
SLE-like syndrome. In our case, the patient may de-
velop complications later in life, and her homozygous
sibling may also develop SLE. It is therefore important
to carefully follow up our patients to prevent the onset
of glomerulonephritis and central nervous system
involvements.
At present, no specific therapy is available for C1q
deficiency, so steroids and immunosuppressive agents
such as hydroxychloroquine (not currently available
in Japan) are used as treatments. Bone marrow trans-
plantation is a potential cure, but it has not yet been
performed in humans [24,25]. Some reports show
that the infusion of FFP restores C1q levels, tempor-
arily complements hemolytic activity, and suppresses
SLE symptoms for a long period [8,24]. It is therefore
a valid therapy for C1q deficiency patients. However,
the long-term administration of FFP increases the
risk of infection and the possibility of side effects
caused by the development of anti-C1q antibodies
[26]. In the light of such risks, alternative treatment
strategies should be considered for this intractable
disease.Consent
Written informed consent was obtained from the
patient for publication of this Case Report and any
accompanying images. A copy of the written consent is
available for review from the Editor-in-Chief of this
journal.Table 5 Measurement of CH50 following transfusion of
FFP in the patient
Time (hr) 0 3 (end of transfusion) 9 24
CH50 (U/ml) <12.0 25.5 24.6 <12.0
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SLE: Systemic lupus erythematosus; ESR: Erythrocyte sedimentation rate;
CRP: C-reactive protein; CH50: Total complement activity; CT: Computed
tomography; FFP: Fresh frozen plasma.
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